DURGA-2
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma
What will happen during the trial?
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 40 patients (estimated)
- Sponsors
- AstraZeneca
- Tags
- CAR T Cell, CD19, B-Cell Maturation Antigen (BCMA), Monotherapy, Single Cohort, High Risk, Open Label
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2146
- NCT Identifier
- NCT07073547
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.